Table 1 Clinical and demographic characteristics of the sarcoidosis patients categorized by absence or presence of positive PET findings

age (yrs)

46 (22-72)

45(24-76)

0.585

sex (male)

11 (61%)

44 (57%)

0.762

time since diagnosis (yrs)

4 (1-20)

2 (1-21)

0.469

Therapy total, number (%)

6 (33%)

20 (26%)

0.461

1/2/3/4

3/0/3/0

10/1/7/2

0.444

ACE (9-25 U/L)

15 (1-29)

18 (3-60)

0.136

sIL-2R (240-3154 pg/mL)

1784 (518-4614)

3434 (1191-15000)

0.002

Neopterin (<2.5 ng/mL)

1.7 (0.8-2.6)

2.8 (0.7-18.2)

0.030

CRP (2-9 μg/mL)

6 (1-15)

6 (1-80)

0.249

CXR stage 0/I

12/1

18/14

0.005

CXR stage II/III/IV

1/3/1

12/8/25

0.449

Total HRCT score

2.9 ± 3.0

6.0 ± 3.9

0.002

FVC total (% pred)

90 ± 22

91 ± 22

0.818

CXR I-II

94 ± 24

103 ± 15

0.174

CXR II-IV

79 ± 14

83 ± 22

0.741

DLCO total (% pred)

78 ± 18

69 ± 20

0.046

CXR I-II

79 ± 17

80 ± 17

0.888

CXR II-IV

71 ± 19

60 ± 19

0.234